Harnessing the chemokine system to home CAR-T cells into solid tumors

Jade Foeng,1,2 Iain Comerford,1 and Shaun R. McColl1,2,*

1Chemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Sciences, The University of Adelaide, Adelaide, SA 5005, Australia
2Carina Biotech, Innovation and Collaboration Centre, The University of South Australia, Adelaide, SA 5000, Australia
*Correspondence: shaun.mccoll@adelaide.edu.au

SUMMARY

CAR-T cell therapy has been heralded as a breakthrough in the field of immunotherapy, but to date, this success has been limited to hematological malignancies. By harnessing the chemokine system and taking into consideration the chemokine expression profile in the tumor microenvironment, CAR-T cells may be homed into tumors to facilitate direct tumor cell cytolysis and overcome a major hurdle in generating effective CAR-T cell responses to solid cancers.

INTRODUCTION

The solid tumor microenvironment is highly complex, housing a plethora of tumor-infiltrating immune cells, reprogrammed stromal cells, and highly heterogeneous malignant cells in a densely barricaded and hostile tissue architecture. These features play critical roles in facilitating or restricting anti-tumor immune responses and in the successful application of chimeric antigen receptor (CAR)-T cell therapies. The trafficking of CAR-T cells into tumors is considered one of the first challenges in developing effective CAR-T cell therapy against solid cancers, as there is often a mismatch or lack of the appropriate migratory signals.

The chemokine system naturally plays a crucial role in the migration of hematopoietic cells during cellular development and effector function,1,2 which can be harnessed to home CAR-T cells directly to solid tumors. Many tumors derived from different tissue origins share similar patterns of chemokine ligand expression, raising the possibility of enhancing CAR-T cell trafficking and infiltration into a diverse array of cancers using select chemokine receptors.3,4 Directed trafficking of CAR-T cells into tumors also provides significant safety advantages as it lowers the required cell dose and reduces dissemination of CAR-T cells into the periphery where off-target toxicity may occur. In this review, we discuss the current landscape of CAR-T cell therapies against solid cancers with emphasis on the mechanisms by which the architecture of solid tumors prevent T cell entry, the key chemokine axes relevant in tumor microenvironments, and how we might enhance CAR-T cell therapies by harnessing these chemokine axes.

CHEMOKINE-MEDIATED CONTROL OF IMMUNE RESPONSES

Chemokine system overview

The immune system is fundamental in protecting living organisms against invading pathogens, clearing dysfunctional or defective cells, and participating in wound repair. These biological processes rely on the intricate and precise spatiotemporal migration of functionally diverse immune cell subsets to sub-anatomical niches.

The choreographed migration of immune cells is largely orchestrated by the chemokine superfamily; a group of small, secreted proteins that function in both homeostatic cellular trafficking and the controlled recruitment of specific cells in response to inflammatory signals. Chemokines also have important roles in the positioning of immune cells within tissues and in lymphoid tissue development,1–3 ensuring cells receive the correct signals to develop and function. Chemokines act as ligands for a family of chemokine receptors that are mainly expressed by cells of hematopoietic origin to migrate toward increasing gradients of their respective chemokines. Structurally, conventional chemokine receptors are seven-transmembrane G protein-coupled receptors which are structurally distinguished from conventional chemokine receptors by an absent or otherwise modified DRYLAIV motif. The chemokine system is further regulated by atypical chemokine receptors (ACKRs), which are structurally distinguished from conventional chemokine receptors by an absent or otherwise modified DRYLAIV motif. This uncouples ACKRs from classical G protein-mediated signaling and results in ACKRs fulfilling a distinct role in regulating chemokine bioavailability by scavenging and internalizing mutual chemokine ligands to which conventional chemokine receptors bind.7–9 The tightly regulated spatiotemporal expression of both conventional chemokine receptors and ACKRs defines migratory

https://doi.org/10.1016/j.xcrm.2022.100543

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
patterns at certain stages of cellular development and effector function, including immune responses in solid tumors. Within the tumor microenvironment (TME), it has been well-established that distinct chemokine receptors recruit a variety of leukocyte subsets into tumors, with naive T cells recruited via CCR7, effector T cells recruited via CXCR3/CCR5/CCR2/CCR6, monocytes and macrophages recruited via CCR2/CCR5, myeloid-derived suppressor cells (MDSCs) recruited via CXCR1/CXCR2/CXCR4/CCR2, and neutrophils recruited via CCR2/CXCR2. However, solid tumors utilize many mechanisms to evade the infiltration of anti-tumorigenic leukocytes, which will be discussed below.

**Inefficient trafficking and penetration of cytotoxic T cells into solid tumors**

In many cancers, limited T cell infiltration of tumors, particularly by CD8+ T cells, is correlated with poor clinical outcomes, whereas enhanced recruitment of T cells into the TME is strongly correlated with improved survival. Tumors exercise many mechanisms to restrict T cell entry and penetration. Physical barriers such as abnormal tumor vasculature and a densely packed extracellular matrix are frequently observed in the stroma of the TME, sequestering T cells outside the tumor parenchyma and preventing their direct contact with tumor cells. Type I collagen and fibronectin are the main structural components of the extracellular matrix of tumor stroma, forming fibers that dictate the trajectory and speed of T cell migration. Ex vivo imaging of viable sections of human non-small cell lung cancer (NSCLC) revealed that T cells migrate along fibers running parallel to blood vessels and epithelial regions, and that the presence of dense fibers immediately adjacent to tumor islets spatially blocks T cell entry.

Furthermore, tumor vasculature frequently exhibits reduced expression of chemokines and adhesion molecules compared with normal vasculature, which limits T cell arrest in tumors. Other components within the tumor stroma and parenchyma may also sequester and distract T cells from forming contact with tumor cells. For instance, two-photon imaging of tumors in a methylcholanthrene (MCA)-induced ovalbumin (OVA)-positive fibrosarcoma mouse model revealed that dendritic cells (DCs) in the tumor parenchyma locally trap T cells by forming long-lasting antigen-specific interactions.

Similarly, in a spontaneous MMTV-PyMT mammary carcinoma mouse model, CD68+ CD11c+ macrophages in the TME formed long-lasting interactions with CD8+ T cells resulting in reduced motility and hostage of CD8+ T cells in the tumor stroma.

Mismatch of migratory signaling elements, particularly between the chemokine profile expressed by tumors and chemokine receptor profile expressed by antigen-specific T cells, is a significant obstacle in T cell trafficking to tumors. By understanding the role of key chemokine receptor axes, these axes may be perceptively co-opted to recruit immune cell subsets to specific sub-anatomical niches, such as solid cancers. Some studies have also demonstrated that CD8+ effector T cells may bypass the requirement for chemokines, by expressing high levels of LFA-1 to form stable adhesions within endothelial vessels in non-tumorigenic inflammatory settings. However, significant evidence highlights chemokines as the main mediators of T cell trafficking into tumors. For instance, gene expression profiling of 44 human metastatic melanoma biopsies showed a significant correlation between T cell-associated genes and chemokine genes. Further RT-PCR and protein arrays revealed that the chemokines CCL2, CCL3, CCL4, CCL5, and CXCL9 were more highly expressed in tumors with increased T cell presence, implying that these chemokines likely promote T cell infiltration. Conversely, poor infiltration of low-grade gliomas and melanomas by CD8+ T cells was significantly correlated with decreased expression of the CXCR3 ligands, CXCL9, CXCL10, and CXCL11 and the adhesion molecule ICAM-1 but had no correlation to immunogenic antigens in humans. Indeed, CXCR3 signaling is frequently downregulated in the TME in many cancers. In a mouse model of human primary ovarian cancer, it was found that epigenetic silencing of Th1-type chemokine expression, mediated by histone modifications and DNA methylation, in tumor cells resulted in diminished effector T cell trafficking into the TME. Administration of epigenetic modifiers to prevent Th1-type chemokine suppression enhanced intratumoral T cell infiltration, and this effect was abrogated when combined with anti-CXCR3. Furthermore, immunoeediting by IFNγ was demonstrated to select for tumor variants that had lost CXCL9 expression in MCA-induced fibrosarcoma and melanoma models. CXCR3 expression by CD8+ T cells was also shown to be suppressed by TGFβ, restricting tumor infiltration in preclinical colorectal cancer mouse models. These studies are consistent with findings in mouse melanoma models in which adoptively transferred CXCR3-deficient OT-I cells displayed reduced infiltration into tumors and decreased control of tumor growth compared with WT OT-I cells. In one of these studies, it was found CXCR3 was involved in stabilizing intravascular adhesion and extravasation of adoptively transferred effector cells through the tumor-vascular interface. In contrast, the expression of certain chemokines has been associated with T cell exclusion from tumor islets. For example, CXCL12 derived from cancer-associated fibroblasts was found to limit intratumor T cell infiltration. This may be due to the chemo-repulsive effect of particularly high concentrations of CXCL12, as observed in a mouse melanoma model, or by CXCL12-mediated sequestration of T cells in the stroma of the TME.

**Chemokines in the tumor microenvironment**

The TME consists of a complex interplay of cells, the recruitment of which is orchestrated by the expression of specific chemokines. These chemokines can be expressed by tumor cells, stromal cells, and infiltrating leukocytes. The specific chemokine profile expressed dictates to a large extent which immune cell subsets migrate into the TME and thus contributes to the type of immune response initiated. Aside from mediating trafficking into the TME, chemokines have also been demonstrated to directly regulate tumor cell proliferation, invasiveness, and metastasis.

CD8+ T cells, Th1 cells, and NK cells represent major players in anti-tumor immunity, with these cells commonly expressing the chemokine receptor CXCR3. CXCR3 on circulating T cells and expression of CXCL9 and CXCL10 in tumor sites has been extensively correlated with increased accumulation of intratumoral T cells and improved survival in many cancers. In an extensive meta-analysis of 5,953 carcinoma specimens from a range of solid tumors including breast, colorectal, ovarian, lung,
and melanoma; CXCL9, CXCL10, and CXCL11 were positively correlated with the density of tumor-infiltrating CD8+ T cells, T1 cells, and NK cells but were inversely correlated with neutrophils at the mRNA level. CXCR3 ligands are expressed by monocytes, endothelial cells, fibroblasts, DC subsets, and certain cancer cells in response to IFNγ provided by T1 cells, cytotoxic T cells, and NK cells. However, a study that sorted YFP-labeled tumor cells, non-hematopoietic CD45+ stromal cells, and distinct populations of APCs in an autochthonous murine melanoma tumor model identified Batf3+ CD103+ cDC1s as the predominant source of CXCL9 and CXCL10. Chemokine production by CD103+ cDC1s recruited anti-tumor CD8+ T cells to tumors, but this was dampened by tumor-intrinsic Wnt/β-catenin pathway activation, which deterred CD103+ DC recruitment into the TME. These DCs were also found to be CCR5+ and recruited to tumors via CCL4 expression by malignant cells. Given the crucial role of CXCL9 and CXCL10 in T cell intratumoral trafficking, several approaches have been explored to increase CXCR3 ligand expression in the TME. This has been achieved via direct delivery methods such as intratumoral injection of recombiant protein or vaccinia virus, which resulted in subsequent tumor regression. Furthermore, co-administration of a specific inhibitor against macrophages and anti-PD-1 was shown to increase CXCL9 and CXCL10 levels in tumors, and delivery of an oncolytic viral vaccine expressing GM-CSF resulted in a significant increase in CXCL10 and CXCL2.

In addition to CXCR3, CCR2 and CCR5 have also been implicated in T cell trafficking to tumors. Many cancers constitutively express the ligand for CCR2, CCL2, as a result of chronic activation of the NF-κB pathway. The expression of inflammatory mediators IL-1, IL-6, TNFα and the immunosuppressive cytokine TGFβ may further promote CCL2 expression. CCL2 can be expressed by a diverse range of cells in the TME including endothelial cells, epithelial cells, fibroblasts, myeloid cells, T cells, and tumor cells. CCL2 has been correlated with tumor progression and attracts immunosuppressive and pro-metastatic TAMs and MDSCs in many cancers including glioblastoma, ovarian, lung, and breast cancers. CCR2 is also used by Treg cells to traffic MDSCs in many cancers including glioblastoma, ovarian, lung, and attracts immunosuppressive and pro-metastatic TAMs and tumor regression. Furthermore, co-administration of a specific inhibitor against macrophages and anti-PD-1 was shown to increase CXCL9 and CXCL10 levels in tumors, and delivery of an oncolytic viral vaccine expressing GM-CSF resulted in a significant increase in CXCL10 and CXCL2.

ENHANCING CAR-T CELL INFILTRATION INTO SOLID TUMORS

Immunotherapy overview

Until relatively recently, intense focus of cancer therapies was directed toward tumor-intrinsic mechanisms, such as targeting

secretion. IL-12. It was recently shown cDC1 recruitment is largely dependent on the secretion of CCL5 and XCL1 by tumor-infiltrating NK cells. However, tumor-derived prostaglandin E2 may block cDC1 recruitment by impairing NK cell viability and chemokine production and downregulating CCR5 and XCR1 chemokine receptor expression by cDC1 cells.

Other chemokines produced by tumors drive recruitment of leukocyte subsets that promote tumor growth. For instance, neutrophils and MDSCs are recruited into the TME by CCL4, CCL5, CCLX, CXCL6, CXCL8, and CXCL12. Similar to CCL2 and CCL5, constitutive activation of NF-κB in many tumors drives production of CXCL8, a ligand for CXCR1 and CXCR2. CXCL8 can significantly impact tumor cell biology, enhancing proliferative, invasive, and migratory capacities of tumor cells through activation of phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. CXCL8 produced by melanoma cells was shown to promote transendothelial migration and lung metastasis by interacting with β2-integrin and ICAM-1, anchoring tumor cells to the vascular endothelium. Tumor-derived CXCL8 also sequesters CXCR1+ and CXCR2+ DCs in tumors, preventing egress and tumor antigen presentation in lymph nodes. Other CXCR2 ligands, CXCL1 and CXCL2, were found to promote breast cancer metastasis by enhancing tumor cell survival via recruitment of CD11b+ Gr1+ myeloid cells. These myeloid cells secreted alarmins and myeloid-related proteins 8 and 14 to attract monocytes that further support cancer cell survival. Furthermore, tumor-derived CXCL8 was shown to induce NET formation by granulocytic MDSCs and neutrophils, which has a demonstrated role in capturing circulating cells and facilitating metastasis. Expectedly, given the many pro-tumorigenic roles of CXCL8, the expression of CXCL8 has been detected in many cancers.

The bioavailability of chemokines in the TME may be further regulated by atypical chemokine receptors such as ACKR4. By scavenging CCL21 in tumors, ACKR4 expressed by gp38+ CD31+ fibroblasts in the tumor stroma was found to regulate CCR7+ CD103+ cDC1 migration into the TME in a murine breast cancer model. Loss of ACKR4 resulted in DC retention in tumors due to accumulation of CCL21, thereby limiting DC egress to tumor-draining lymph nodes and potentially promoting local anti-tumor CD8+ T cell responses. Aside from ACKR4, ACKR2 and ACKR3 also have demonstrated roles in shaping tumor biology via chemokine scavenging.

In summary, chemokines act to orchestrate migration of diverse leukocyte subsets into the TME, the cellular functions of which dictate the type of immune response generated. The influence of this specific immune response on tumors is now appreciated to have important consequences for driving or inhibiting tumorigenesis. The next section will explore how anti-tumor immune responses may be enhanced therapeutically in the form of cancer immunotherapy.
the hyperproliferative nature of tumors using chemotherapy and radiotherapy. However, as understanding of the role of the TME and immune contexture has improved, more specific and novel targets have been identified. For instance, tumors frequently exploit checkpoint pathways to dampen anti-tumor T cell activation and function. Checkpoint inhibitor therapy is a class of immunotherapy that acts to prevent this exploitation, which has received significant attention in the past two decades.

T cell-targeted modulators such as α-CTLA-4 and α-PD-1 are currently used as a first or second line of treatment in around 50 cancer types, particularly metastatic melanoma. However, despite long-lasting remission and disappearance of detectable metastases in 20% of metastatic melanoma patients, a large proportion of patients remain partially responsive or non-responsive. An analysis of 209 advanced melanoma patients identified multiple parameters that correlate with prolonged survival following ipilimumab (α-CTLA-4) treatment, including low baseline serum lactate dehydrogenase levels and monocyte, eosinophil, and lymphocyte abundance. Furthermore, CyTOF analysis of peripheral blood from melanoma patients identified predictive biomarkers for non-responders to α-PD-1 and α-CTLA-4 therapies including an absence of tumor-infiltrating T cells and CD69+ CCL4-secreting NK cells. This is consistent with the correlation between high levels of IFNγ and IFNγ-inducible genes, such as CXCL9, with α-PD-L1 responsiveness in melanoma, NSCLC, and renal cell carcinoma patients. It is also consistent with the finding that the anti-tumor immune response induced by α-PD-1 is dependent on CXCL9 produced by intratumoral CD103+ DCs, which potentially facilitates CXCR3-dependent DC-T cell interactions in the TME. Furthermore, single cell analysis of 18,291 individual immune cells from 48 melanoma patients treated with checkpoint inhibitor immunotherapy identified a subset of TcF7+ TIM-3+/CD39+ CD8+ tumor-infiltrating lymphocytes that respond to α-PD-1 immunotherapy. While the stratification of patients likely to respond to α-PD-1, α-CTLA-4, and related therapies using these parameters may simplify the treatment process, it emphasizes a great need for alternative methods to treat patients who are unresponsive or acquire resistance to such therapies.

Adaptive T cell therapies represent a promising avenue, utilizing ex vivo activated patient-derived cells, which have been expanded to sufficient numbers for therapeutic use. Pioneering work by Rosenberg and colleagues demonstrated that IL-2-expanded T cells significantly inhibited tumor progression in a mouse model of colorectal cancer and in patients with metastatic melanoma. However, antigen-specific T cell responses remained a key obstacle, due to the lack of tumor antigen recognition and MHC class I downregulation by tumors. More recent achievements in adoptive T cell therapy have circumvented the need for MHC-dependent activation, achieving antigen-specific recognition of tumor cells in the form of CAR-T cell therapy. Advancements within this field will be discussed in detail in the next section.

**CAR-T cell therapy directed toward hematological and solid cancers**

CD19 was the first of a series of B cell markers to be targeted with CAR-T cell therapy to treat a range of hematological malignancies. CD19 is widely expressed on B cells in both mice and humans and is a co-receptor involved in fine-tuning pre-BCR/BCR signaling and B cell fate decisions. Clinical trials of CD19-targeting CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL) demonstrated unprecedented clinical responses, reaching 80%–93% complete remission rates in patients with relapsed or refractory B-ALL and a long-term remission of 20 months in patients with a low disease burden of relapsed B-ALL. The unprecedented success observed in these clinical trials culminated in the FDA approval of tisagenlecleucel (Kymriah; Novartis), a CD19-targeting CAR-T cell therapy for the treatment of relapsed or refractory B-ALL in 2017. This was followed with the FDA approval of axicabtagene ciloleucel (Yescarta; Gilead) to treat large B cell lymphoma also in 2017 and brexucabtagene autoleucel ( Tecartus; Gilead) to treat mantle cell lymphoma in 2020. Most recently in February 2021, lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb) was approved for patients with relapsed or refractory large B cell lymphoma.

All of these therapies are directed toward CD19.

Despite remarkable clinical outcomes of CAR-T cell therapy against hematological malignancies, this success has not yet translated to solid tumors. Solid tumors present numerous challenges that are absent in disseminated hematological cancers such as: heterogeneous antigen expression, physical and molecular barriers that block T cell entry, acidic and hypoxic conditions, and a highly immunosuppressive TME. These features are illustrated in Figure 1. While there are a growing number of clinical trials currently investigating CAR-T cell therapies against solid tumors, this is disproportionate to the large number of those investigating these therapies in hematological cancers. Meta-analysis of 22 clinical studies revealed a 9% overall response rate following CAR-T cell treatment in patients with solid tumors. The first challenge in developing an effective CAR-T cell therapy against solid cancers is the identification of suitable tumor antigens that are either not expressed or expressed at lower levels on healthy cells to avoid on-target off-tumor complications. Consideration of both the identity and antigen density of a select tumor antigen is crucial in developing an effective CAR-T cell therapy as target antigen density on tumor cells has been positively correlated with increased activation and cytokine production of CAR-T cells. However, antigen density on malignant cells relative to healthy cells also dictates the optimal affinity of the CAR such that healthy cells can be spared from CAR-T cell-mediated cytotoxicity. It is also important to emphasize that although there has been limited success reported in clinical trials of CAR-T cell therapies against solid cancers, most are in phase I trials, with the primary objective to test safety, dosing, and engraftment rather than efficacy. The most commonly targeted solid tumor antigens in current preclinical and clinical trials include GD2, EGFR, ROR1, PSMA, EpCAM, HER2, and mesothelin. The results from preclinical and clinical testing of CAR-T cells targeting some of these antigens are described in detail below. However, as this list is non-exhaustive, further information on CAR-T cell clinical trials against solid cancers can be found at [http://www.clinicaltrials.gov](http://www.clinicaltrials.gov).

GD2 is a ganglioside abundantly expressed on neuroblastoma cells, which has been the subject of many clinical trials of CAR-T...
cell therapy. Neuroblastoma is an aggressive and debilitating form of childhood brain cancer with a 5-year survival rate of only around 50% with current treatments. GD2 is also expressed by melanoma, lung cancer, and other brain cancer subtypes. However, low level expression by the basal regions of the brain, cerebellum, and peripheral nerves have resulted in fatal toxicity in preclinical, and possibly, clinical trials. For instance, in a preclinical model of human neuroblastoma xenografts in immunocompromised NOD-scid IL2Rg null (NSG) mice, extensive infiltration and proliferation of high affinity GD2-targeting CAR-T cells resulted in lethal neuronal destruction, which was also observed in non-tumor-bearing mice injected with CAR-T cells. However, this has been challenged by a separate group that used a CAR with the same high affinity GD2 binder and reported no neurotoxicity in NSG mice. Safety of GD2-targeting CAR-T cells has also been demonstrated in several clinical trials. To improve safety, a recent clinical trial designed and tested GD2-targeting CAR-T cells with an intermediate affinity GD2 binding domain and "suicide" gene composed of two epitopes that bind to the α-CD20 antibody, rituximab, in neuroblastoma patients. Despite evidence of CAR-T cell activation and anti-tumor responses in a proportion of these patients, no neurological toxicity was observed. However, in this study, none of the patients showed objective clinical responses 28 days after infusion, highlighting the need to promote CAR-T cell persistence, which has been a recurring challenge in developing effective GD2-directed CAR-T cell therapies.

EGFR is a transmembrane receptor tyrosine kinase expressed in tissues including the skin, kidneys, and gastrointestinal tract, which is abnormally upregulated in numerous epithelial tumors, such as lung, pancreatic, colorectal, breast, and head and neck squamous cell carcinomas. Overexpression of EGFR by tumors is correlated with tumor progression and has been the focus of numerous cancer therapies, including CAR-T cell therapy. The most common oncogenic mutant of EGFR is EGFR variant III (EGFRvIII), which is expressed in 24%–67% of glioblastomas, a highly aggressive subtype of brain tumors. CAR-T cells targeting EGFRvIII were found to produce IFNγ and lyse glioma stem cell lines in response to tumor antigen stimulation. Furthermore, in preclinical mouse models of glioblastoma, delivery of EGFRvIII-targeting CAR-T cells reduced tumor growth and prolonged survival compared with irrelevant, control CD19-targeting CAR-T
cells when tumors were injected subcutaneously, MRI following intracranial implantation of tumor cells revealed significant reduction in the tumor mass, which was associated with enhanced CAR-T cell presence in the bone marrow, spleen, and brain. However, despite promising preclinical results, limited success has been reported in clinical trials, with one trial reporting a 6% complete response rate in patients with EGFR-positive, advanced biliary tract cancers and another reporting a 5.6% 6-month progression-free survival rate in patients with glioblastoma.

The receptor tyrosine kinase-like orphan receptor 1 (ROR1) has also received attention as a target of CAR-T cell therapy as it is expressed by a range of cancers including B-lymphoid cancers and epithelial cancers such as lung, breast, colorectal, pancreatic, and ovarian. It is also expressed by some immature B cell precursors and adipocytes, but it is not expressed on normal mature B cells. ROR1-directed CAR-T cells effectively lysed ROR1+ breast cancer and kidney cancer cell lines in vitro and inhibited tumor growth to the same extent as CD19-targeting CAR-T cells in a human mantle cell lymphoma mouse model. ROR1-directed CAR-T cells have also demonstrated potent anti-tumor activity in three-dimensional microphysiologic A549 lung and MDA-MB-231 breast cancer models, which recapitulate certain architectural and phenotypical features of tumors. This was determined by quantification of IFNγ and IL-2 secretion into the culture medium, tumor cell apoptosis, and T cell proliferation. A clinical trial of ROR1-targeting CAR-T cells in patients with hematological and epithelial cancers is currently ongoing (NCT02706392).

Prostate-specific membrane antigen (PSMA) is a membrane-localized carboxypeptidase, which is expressed ubiquitously in prostate tissue and is upregulated in prostate cancer. However, it is also expressed in various organs including the kidney and brain, which has resulted in lethal on-target off-tumor toxicities in clinical trials. In one clinical study, two out of five patients with advanced hormone-refractory prostate cancer displayed only partial clinical responses to PSMA-targeting CAR-T cells. To overcome the highly immunosuppressive TME, PSMA-directed CAR-T cell have been developed with a TGFβ-dominant negative receptor, referred to as DNRII, which lacks the intracellular domains required for downstream TGFβ signaling. DNRII-modified PSMA-directed CAR-T cells exhibited enhanced proliferation upon stimulation with PSMA-expressing cancer cell lines, which was associated with an increased frequency of central memory CD8+ T cells and decreased FoxP3 expression. Furthermore, these cells were also able to significantly inhibit the growth of PC3-PSMA+ tumors in NGS mice compared with conventional PSMA-targeting CAR-T cells. However, DNRII-modified PSMA-targeting CAR-T cells have also been associated with fatal immune effector cell-associated neurotoxicity syndrome in a recent clinical trial (NCT03089203).

While some CAR-T cell therapies are directed to tumor antigens expressed by multiple tumor types, such as EGFR, GD2, and ROR1, a large proportion target only one or a few cancer subtypes. The relatively small pool of known solid tumor antigens results in current CAR-T cell therapies acting on a limited number of solid cancers. Solid cancer treatments that act universally on different cancers have major advantages in reducing cost and production time, which is crucial for patients with poor prognosis. One potential method to develop a universal CAR-T cell therapy is through sophisticated synthetic design of CAR-T cells, such that their antigen binding capacity is separated from the signaling domains to allow for target antigen flexibility. The two component system introduces an “ON” switch as a soluble antigen binding adaptor must be administered for the CAR-T cells to become activated. Moreover, multiple tumor antigens may be targeted via simultaneous administration of multiple antigen binding adaptors, without further modification of T cells. This may be highly beneficial in combating the heterogeneous expression of antigens often seen in solid tumors. The first example of this utilized biotin-binding immune receptors (BBIR), which comprised an extracellular-modified avidin protein linked to an intracellular T cell signaling domain, engineered onto T cells. Here, the BBIR binds to cancer cells pre-targeted with specific biotinylated molecules. Recently, a more tailored approach was developed that utilized leucine zippers to bind the scFv portion to intracellular signaling domains. Upon administration of multiple scFv adaptors, these split, universal, and programmable (SUPRA) CAR-T cells were able to target multiple antigens, which was demonstrated to prevent the emergence of antigen loss or escape variants, as similarly observed with bispecific or tri-specific CD19/CD20/CD22-targeting CAR-T cells.

As discussed, target antigen selection is often a limiting step in targeting solid cancers with CAR-T cell therapy, as antigens are often heterogeneously expressed, expressed by only one or a few cancer subtypes, or are also present on healthy tissues. Careful consideration of tumor target antigens and innovative CAR-T cell design have provided promising avenues in developing effective and potentially universal therapies against solid cancers. Upon selection of a suitable target antigen, the next major challenge is in homing CAR-T cell infiltration into often densely barricaded and hostile solid tumors.

**Chemokine-directed CAR-T cell therapy**

T cell trafficking into tumors remains a major hurdle in generating an effective CAR-T cell therapy against solid cancers. In some mouse tumor models, less than 1%–2% of adoptively transferred T cells were found to infiltrate solid tumors. Indeed, spatiotemporal imaging of PSMA-targeting CAR-T cell migration in prostate tumor-bearing mice revealed a large proportion were present in the thyroid, salivary glands, stomach, and bladder, with only 0.2% of total transferred cells located in the tumor. Directed trafficking of CAR-T cells also provides significant safety advantages as it lowers the required cell dose and reduces dissemination in the periphery where on-target off-tumor toxicity may occur. Harnessing the chemokine system, which naturally plays a crucial role in the migration of hematopoietic cells, has therefore been identified as an attractive method to improve the activity of CAR-T cells by enhancing their trafficking into tumors. Chemokine receptor axes that have been studied as an approach to enhance intratumoral T cell trafficking are illustrated in Figure 2.

Understanding the expression profile of chemokines in the TME may inform which chemokine axes can be utilized to enhance CAR-T cell trafficking into solid tumors. Given the
numerous pathological effects of CXCL8 in angiogenesis, cancer stem cell survival, and recruitment of immunosuppressive myeloid cells, it is unsurprising that CXCL8 is strongly correlated with disease burden in many solid cancers including melanoma, renal cell carcinoma, NSCLC, pancreatic, breast, and ovarian.63–65,67,124–127 CXCL1 and CXCL2 are also highly expressed in many solid cancers.127–129 Indeed, the chemokine receptors that bind to these ligands, CXCR1 and CXCR2 have been co-opted as tumor-homing signals in several preclinical CAR-T cell therapies. For example, CXCR1- and CXCR2-modified CD70-targeting CAR-T cells showed enhanced intratumoral accumulation and persistence in a glioblastoma xenograft model, resulting in complete tumor regression and long-lasting immunological memory in rechallenge experiments compared with non-modified CAR-T cells. In this model, fractionated local radiation increased expression of CCL2, CCL20, and CXCL1, 2, and 8 in tumors, and early intratumoral infiltration occurring in 3 days or less post-T cell transfer was a reliable indicator of survival. Furthermore, CXCR1/2-modified CAR-T cells siphoned off CXCL8 in vitro, potentially neutralizing pro-tumorigenic CXCL8 from tumors and improving the efficacy of other antitumor therapies following co-administration.66 Similarly, transduction of pmel-1 transgenic T cells to express CXCR2 resulted in a 2-fold increase in T cell presence in gp100-transduced colorectal tumors by 6 days post-transfer. This was associated with a 50% reduction in tumor growth compared with administration of non-CXCR2-modified T cells when both were combined with DC vaccination and IL-2 administration.69 In a separate study, transduction of lymphocytes isolated from the tumor ascites of ovarian cancer patients to express CXCR2 resulted in T cell migration into autologous and allogeneic ascites in vitro, which were found to highly express CXCL1 and CXCL8.64 These
Moreover, CXCR2-expressing CAR-T cells directed to integrin αvβ6 controlled tumor growth in a human pancreatic tumor xenograft mouse model more effectively compared with non-CXCR2-expressing CAR-T cells. However, it is important to note that in many of these studies, in which T cell infiltration is quantified several days post-transfer (at the earliest), the underlying mechanism, whether that be increased trafficking or proliferation, increased retention within tumors, or decreased apoptosis of CAR-T cells was not differentiated.

Another chemokine axis of interest in enhancing intratumoral trafficking of adoptive cell immunotherapy is CCL2-CXCR2. For instance, GD2-targeting CAR-T cells were transduced to express CCR2b after CCL2 was identified to be highly expressed by neuroblastoma cell lines and primary tumor biopsies. This resulted in increased CAR-T cell intratumoral accumulation in subcutaneous human neuroblastoma xenografts in SCID mice at d2 and d3 post-T cell transfer, which was accompanied by increased CAR-T cell proliferation and persistence and reduced tumor burden compared with mice receiving GD2-targeting CAR-T cells without CCR2b. However, manufacture involved sequential transduction of two separate vectors containing the GD2 CAR and CCR2b, resulting in low transduction efficiency. Patient pleural fluids and cell lines of malignant pleural mesothelioma (MPM) were also found to express high levels of CCL2. Therefore, CAR-T cells targeting mesothelin, a glycoprotein expressed at high levels on MPM, ovarian cancer, and pancreatic cancer, were transduced to express CCR2b. This resulted in improved anti-tumor efficacy against advanced human MPM tumor xenografts in immunocompromised mice compared with CCR2-negative CAR-T cells. Improved anti-tumor efficacy was associated with a 12.5-fold increase in the presence of CAR-T cells within tumors 5 days following T cell transfer. However, similar to the GD2-targeting CAR-T cells described in the previous study, lentiviral transduction with two separate vectors resulted in low efficiency with 30% CAR-positive in the control mesothelin-targeting CAR-T cell population and 19% CAR- and CCR2-double positive in the dual-transduced population. Aside from neuroblastoma and MPM, CCL2 is also constitutively highly expressed by other tumors including glioma, melanoma, lung cancer, and Hodgkin’s lymphoma, positioning CCR2 as a potential candidate for enhancing intratumoral infiltration of adoptive cell therapies to these cancers.

The use of CXCL16-CXCR6, CXCL12-CXCR4, and CCL1-CXCR8 chemokine axes to improve adoptive T cell intratumoral trafficking has also received some attention in a limited number of studies. CXCL16 exists in two distinct forms, whereby transmembrane CXCL16 is converted into a soluble form via ADAM10- and ADAM17-mediated cleavage and subsequent shedding. Transmembrane CXCL16 mediates cell adhesion, whereas soluble CXCL16 acts as a chemoattractant. As CXCL16 was found to be highly expressed by OVA-expressing murine pancreatic cancer models and patient pancreatic duct adenocarcinoma (PDAC) tumor biopsies, OT-I cells, murine EpCAM-targeting CAR-T cells, and human mesothelin-targeting CAR-T cells were transduced to express CXCR6. CXCR6-transduced EpCAM-targeting CAR-T cells induced significant tumor regression with complete tumor rejection in 40% of mice, which was superior to the regression observed with unmodified control, CXCR3-transduced, or CCR4-transduced EpCAM-targeting CAR-T cells. Here, CXCR3 and CCR4 were tested in parallel due to high expression of their ligands in murine pancreatic mouse models, and tumor cells were transduced to express EpCAM. Intravital and two-photon imaging confirmed accumulation of CXCR6-transduced OT-I cells within murine pancreatic tumors. Meanwhile CXCL6-transduced mesothelin-targeting CAR-T cells significantly inhibited tumor growth of patient-derived pancreatic cancer xenografts in immunocompromised mice and produced significantly higher levels of IFNγ upon in vitro stimulation with patient-derived organoids (compared with control CAR-T cells and control T cells, respectively).

Aside from pancreatic cancer, CXCL16 was also found to be highly expressed in multiple cancer types such as ovarian, breast, prostate, cervical, lung, and colorectal cancers according to analysis of The Cancer Genome Atlas. However, stratification of CCL1 in cancer tissues. However, the transmembrane form may inhibit tumor proliferation, which is associated with CXCR6* lymphocyte accumulation in the TME. CAR CXCR6 may also have an additional role, as reported in a separate study that demonstrated CXCR6 expression was critical for sustained anti-tumor efficacy of cytotoxic T cells in an antigen-specific model of murine melanoma. In that model, it was revealed cytotoxic CXCR6+ CD8+ T cells were positioned in a perivascular niche of the tumor stroma, localized with CCR7* cDCs that express CXCL16. Through cell contact-dependent trans-presentation of IL-15 by cDCs, interaction with cDCs provided key survival and proliferation signals to cytotoxic T cells.

Similarly to CXCL16, the ligand for CXCR4, CXCL12 was found to be highly expressed by cancer-associated fibroblasts in PDAC, NSCLC, and breast cancer, and both CXCR4 and CXCL12 have been found to be upregulated in many cancers. Indeed, CXCL12 along with its receptors CXCR4 and CXCR7 have been strongly correlated with enhanced proliferation, angiogenesis, and metastasis of multiple cancers. To enhance homing of CAR-T cells into the CXCL12-rich bone marrow of mice transplanted with patient-derived acute myeloid leukemia, CD25-targeting CAR-T cells were modified to co-express CXCR4. Administration of CXCR4-modified CD25-targeting CAR-T cells resulted in decreased tumor burden, although differences in trafficking were not explicitly investigated. Currently, CXCR4-modified B cell maturation antigen (BCMA)-targeting CAR-T cells are being investigated in a clinical trial of multiple myeloma (NCT04727008).

Known mechanisms involved in recruitment to the TME, such as the CCL1-CXCR8 axis used by Treg cells, may also be co-opted to enhance CAR-T cell trafficking. The use of CCL1-CXCR8 by Treg cells has been demonstrated in analyses of human breast cancer and PDAC biopsies, which found a strong correlation between CCL1 and FoxP3 expression and highlighted an upregulation of CCL1 in cancer tissues. However, exploitation of the CCL1-CXCR8 axis may expose CAR-T cells to immunosuppression.
by localizing these cells with TGFβ3-expressing Treg cells, which utilize the same chemokine axis. Thus, to simultaneously combat immunosuppression and improve trafficking into solid tumors, CCR8 and the TGFβ3-insensitive receptor, DNRII, were engineered onto murine EpCAM-targeting CAR-T cells. This resulted in significant tumor inhibition and improved survival in a murine pancreatic tumor model, which was transduced to express the antigen EpCAM, compared with unmodified CAR-T cells. In contrast, CAR-T cells that were engineered to express CCR8 alone had a minimal effect on tumor growth, likely due to TGFβ3-mediated immunosuppression. Similarly, dual CCR8-and DNRII-expressing mesothelin-targeting CAR-T cells elicited improved tumor regression and survival against human pancreatic cancer xenografts, which were transduced to express mesothelin. Consistent with the murine setting, significant tumor regression was only observed for CAR-T cells that expressed both CCR8 and DNRII and not CCR8-expressing CAR-T cells, which showed no additional improvement over unmodified CAR-T cells. Enhanced tumor regression was associated with increased presence of dual DNRII- and CCR8-expressing CAR-T cells within tumors compared with CAR-T cells expressing CCR8 or DNRII alone. However, as with the previous studies involving chemokine receptor-modified CAR-T cells, it is unclear whether the findings in this study are a result of increased proliferation, trafficking, survival, or intratumoral retention, as analysis was performed 19 days post-T cell administration in endpoint tumors.

Furthermore, the elevated expression of other chemokines such as CCL5, CXCL5, CX3CL1, CCL17, CCL20, and CCL22 across various tumor models and patient biopsies may also provide potential avenues to enhance CAR-T cell trafficking into tumors. For instance, following the finding that multi-nucleated Reed-Sternberg cells of Hodgkin’s lymphoma express the ligands for CCR4, CCL17, and CCL22, a study found CCR4 co-expression on CD30-targeting CAR-T cells enhanced anti-tumor efficacy against a subcutaneous Hodgkin’s lymphoma human xenograft model. In a separate study, the CCR4-CCL22 axis was also utilized to enhance intratumoral recruitment of cytotoxic T cells in an antigen-specific murine pancreatic tumor model, resulting in enhanced anti-tumor efficacy of CCR4-transduced T cells. Similarly, following the identification of CX3CL1 expression in human colorectal cancer biopsies and cancer cell lines, transduction of human primary T cells to express CX3CR1 resulted in enhanced intratumoral accumulation of these cells in endpoint human colorectal tumor xenografts in immunocompromised mice.

To supplement CAR-T cell function, the chemokine system has also been used to recruit endogenous immune subsets to tumors. For instance, CD20-targeting CAR-T cells engineered to simultaneously express IL-7 and CCL21 were found to recruit T cells and DCs to tumors, mimicking the role of fibroelastic reticular cells in the T cell zone of secondary lymphoid organs. Ex vivo analysis of modified CAR-T cells showed increased diversity of TCR repertoires compared with that at pre-injection, indicating epitope spreading to recognize different tumor antigens. This observation was consistent with results in rechallenge experiments, which showed delayed tumor growth of parental CD20-negative mast cell tumors in mice previously injected with CD20-positive tumor cells and IL-7- and CCL19-expressing CD20-targeting CAR-T cells. Similarly, CAR-T cells targeting claudin-18.2 (CLDN18.2) were engineered to co-express IL-7 and CCL21 in a separate study. In parallel analysis, IL-7- and CCL21-expressing CAR-T cells were more effective than IL-7- and CCL19-expressing CAR-T cells in suppressing tumor growth in murine pancreatic, breast, and liver tumor models, which was associated with enhanced CAR-T cell and DC infiltration into tumors. This may be related to differing chemotactic abilities of CCL19 and CCL21. Furthermore, reduced tumor angiogenesis was observed following administration of IL-7- and CCL21-expressing CAR-T cells, possibly due to the angiostatic activity of CCL21. However, increased concentrations of CCL21 in the TME may play a detrimental role in some contexts. In a separate study, tumor-derived CCL21 was found to shift the immune response from immunogenic to tolerogenic in mouse melanoma models, associated with the recruitment of Treg cells, MDSCs, and naive T cells that are subsequently polarized toward Treg differentiation within the TGFβ3-enriched immunosuppressive cytokine milieu.

While the local delivery of chemokines into the TME enhanced the recruitment of immune subsets in these studies, this process may be highly complex and context-dependent. This was exemplified in a separate study, which showed that delivery of CXCL11 by a first dose of mesothelin-targeting CAR-T cells did not improve anti-tumor efficacy of a second dose of CAR-T cells in a human malignant mesothelioma xenograft mouse model. This was accompanied by a significant reduction in human CD3+ cell accumulation in endpoint tumors compared with mice receiving two doses of control mesothelin-targeting CAR-T cells. In contrast, delivery of CXCL11 via an oncolytic vaccinia virus in a murine subcutaneous lung cancer model resulted in an increased frequency of CAR-T cells in endpoint tumors and improved anti-tumor efficacy. The differences between the two delivery methods was proposed to be due to chronic secretion of CXCL11 by CAR-T cells driving continuous autocrine activation of CXCR3 and sustained calcium signaling. Indeed, this may be an important consideration for all CAR-T cells transduced to express chemokine receptors as sustained calcium signaling has been reported to induce T cell anergy in a calcineurin-dependent pathway. Furthermore, CXCL11 has been shown to inhibit angiogenesis, which may have resulted in reduced T cell trafficking into tumors in the previous study. However, this contrasts the results presented by Luo and colleagues, in which CCL21 delivery by CAR-T cells led to reduced angiogenesis but increased CAR-T cell and DC recruitment into tumors. The conflicting results presented in these studies highlights the complicated mechanisms by which chemokine-mediated signaling may influence CAR-T cell recruitment and activity.
or CAR-T cells engineered to deliver ECM-modifying enzymes such as heparanase and hyaluronidase into the TME. Taken together, these preclinical studies highlight the potential in harnessing the chemokine system to home CAR-T cells into tumors and facilitate direct tumor cell cytolysis, resulting in significant improvements in CAR-T cell efficacy against solid cancers. Delivery of chemokines such as CCL19 and CCL21 into the TME by CAR-T cells may also act as a strategy to promote anti-tumorigenic DC and T cell recruitment into solid tumors while targeting architectural components of the TME via ECM-modifying enzymes and depletion of cancer-associated fibroblasts may further enhance intratumoral infiltration.

CONCLUSIONS

Recent clinical advances have demonstrated the efficacy of immunotherapy in the eradication of tumors. While CAR-T cell therapy has achieved unprecedented success in treating hematological malignancies, solid tumors and their associated tumor microenvironment present many challenges that prevent the delivery of effective therapy. One of the major challenges lies in targeting CAR-T cell migration into often densely barricaded and hostile solid tumors. The chemokine system naturally plays a critical role in the migration of hematopoietic cells, which can be harnessed to home CAR-T cell therapy directly into tumors. Identification of key chemokine axes such as CXCL8/CXCR2 and CCL2/CCR2 in the TME has led to the promising preclinical results demonstrating enhanced infiltration of chemokine receptor-modified CAR-T cells into solid tumor models, which is associated with significant improvement in anti-tumor efficacy. Furthermore, many chemokines such as CCL2, CXCL8, and CXCL16 are widely expressed in different solid tumors, potentially providing an avenue to target CAR-T cells into diverse cancer types using select chemokine receptors. By addressing this initial challenge, CAR-T cell therapies may be developed that are efficiently recruited to, and specifically recognize, a large repertoire of malignant cells within solid tumor contexts and begin the translation of CAR-T cell therapy from hematological malignancies to solid cancers.

ACKNOWLEDGMENTS

This research was funded in part by National Health and Medical Research Council project grants 1030247 and 1105312 to S.R.M. and I.C. J.F. is the recipient of the Research Training Program Scholarship and Lady Barr Smith Scholarship for Cancer Research. The graphical abstract and figures were created with Biorender.com.

AUTHOR CONTRIBUTIONS

Writing – original draft, J.F.; writing – review & editing, J.F., I.C., S.R.M.; funding acquisition, S.R.M. and I.C.

DECLARATION OF INTERESTS

J.F. and S.R.M. are employed by Carina Biotech. S.R.M. and I.C. are inventors on patent US-2020-0,054,677-A1, which is licensed to Carina Biotech. S.R.M. is on the scientific advisory board at Tizona Therapeutics.

REFERENCES

1. Cyster, J.G. (1999). Chemokines and cell migration in secondary lymphoid organs. Science 286, 2098–2102.
2. Rot, A., and von Andrian, U.H. (2004). Chemokines in innate and adaptive host defense: basic chemokineese grammar for immune cells. Annu. Rev. Immunol. 22, 891–928.
3. Nagarsheth, N., Wicha, M.S., and Zou, W. (2017). Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17, 559–572.
4. Vilge, A.E., and Richmond, A. (2019). Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immuno-therapy. Front. Immunol. 10, 1–14.
5. Lauffenburger, D.A., and Horwitz, A.F. (1996). Cell migration: a physically integrated molecular process. Cell 84, 359–369.
6. SenGupta, S., Parent, C.A., and Bear, J.E. (2021). The principles of directed cell migration. Nat. Rev. Mol. Cell Biol. 22, 529–547.
7. Comerford, I., Harata-Lee, Y., Bunting, M.D., Gregor, C., Kara, E.E., and McColl, S.R. (2013). A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. Cytokine Growth Factor Rev. 24, 269–283.
8. Nibbs, R.J.B., and Graham, G.J. (2013). Immune regulation by atypical chemokine receptors. Nat. Rev. Immunol. 13, 815–829.
9. Whyte, C.E.; Osman, M., Kara, E.E., Abbott, C., Foeng, J., McKenzie, D.R., Fenix, K.A., Harata-Lee, Y., Foyle, K.L., Boyle, S.T., et al. (2020). ACKR4 restrains antitumor immunity by regulating CCL21. J. Exp. Med. 217, e20190634.
10. Gregor, C.E., Foeng, J., Comerford, I., and McColl, S.R. (2017). Chapter four - chemokine-driven CD4+ T cell homing: new concepts and recent advances. In Advances in Immunology, F.W. Alt, ed. (Academic Press), pp. 119–181.
11. Naito, Y., Saito, K., Shiba, K., Ohuchi, A., Saijenji, K., Nagura, H., and Ohtani, H. (1998). CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58, 3491–3494.
12. Zhang, L., Conejo-Garcia, J.R., Katsaros, D., Gimotty, P.A., Massobrio, M., Regnani, G., Makriannakis, A., Gray, H., Schlenger, K., Liebman, M.N., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213.
13. Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A.A., Frosina, D., Grigat, S., Ambroseon, C., et al. (2005). Intraepi- thelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. 102, 18538–18543.
14. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006). Type, density, and location of immune cells within human colo-rectal tumors predict clinical outcome. Science 313, 1960–1964.
15. Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015). Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249–253.
16. Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Barrin, S., Kantarli- Mimoun, C., Bercovici, N., Guérin, M., Biton, J., Ouakrim, H., et al. (2018). Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc. Natl. Acad. Sci. 115, E4041–E4050.
17. Bougerara, H., Mansuet-Lupo, A., Alifano, M., Ngo, C., Damotte, D., Le Frère-Belda, M.-A., Donnadieu, E., and Peranzoni, E. (2015). Real-time imaging of resident T cells in human lung and ovarian carcinomas reveals how different tumor microenvironments control T lymphocyte migration. Front. Immunol. 6, 1–12.
18. Salmon, H., Francziszkiewicz, K., Damotte, D., Dieu-Noujeim, M.-C., Val- idire, P., Trautmann, A., Mami-Chouaib, F., and Donnadieu, E. (2012). Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122, 899–910.

19. Debets, R., Donnadieu, E., Chouaib, S., and Coukos, G. (2016). TCR-engineered T cells to treat tumors: seeing but not touching? Semin. Immunol. 28, 10–21.

20. Boissonnas, A., Licata, F., Poupel, L., Jacquelin, S., Fetter, L., Krunef, B., Théry, C., Amligorena, S., and Combadière, C. (2013). CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network. Neoplasia 15, 85–94.

21. Shulman, Z., Cohen, S.J., Roediger, B., Kalchenko, V., Jain, R., Grabov- sky, V., Klein, E., Shinder, V., Stoler-Barak, L., Feigelson, S.W., et al. (2012). Transendothelial migration of lymphocytes mediated by intraendothelial vesicle stores rather than by extracellular chemokine deposits. Nat. Immunol. 13, 67–76.

22. Walch, J.M., Zeng, Q., Li, Q., Oberbamscheidt, M.H., Hoffman, R.A., Wil- liams, A.L., Rothstein, D.M., Shlomchik, W.D., Kim, J.V., Camrind, G., et al. (2013). Cognate antigen directs CD8+ T cell migration to vascularized transplants. J. Clin. Invest. 123, 2663–2671.

23. Harlin, H., Meng, Y., Peterson, A.C., Zha, Y., Tretiakova, M., Stingluff, C., McKeel, M., and Gajewski, T.F. (2009). Chemokine expression in melano- mata metastases associated with CD8+ T-cell recruitment. Cancer Res. 69, 3077–3085.

24. Weenink, B., Draaisma, K., Ooi, H.Z., Kros, J.M., Sillevis Smitt, P.A.E., et al. (2013). CCR2 influences T regulatory cell migration to tumors. J. Immunol. 190, 832–841.

25. Gunderson, A.J., Yamazaki, T., McCarty, K., Fox, N., Phillips, M., Ache, A., Blair, T., Whiteford, M., O’Brien, D., Ahmad, R., et al. (2020). Tgfβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking. Nat. Commun. 11, 1749.

26. Chhelda, Z.S., Sharma, R.K., Jala, V.R., Luster, A.D., and Haribabu, B. (2016). Chemotactic receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors. J. Immunol. 197, 2016–2026.

27. Mikuccki, M.E., Fisher, D.T., Matsuzaki, J., Skitzki, J.J., Gaulin, N.B., Mu- hitch, J.B., Ku, A.W., Frelinger, J.G., Odunsi, K., Gajewski, T.F., et al. (2015). Non-redundant requirement for CXCR3 signaling during tumor- cidal T-cell trafficking across tumor vascular checkpoints. Nat. Comm- un. 6, 7458.

28. Feig, C., Jones, J.O., Kraman, M., Wells, R.I.B., Deonarine, A., Chan, D.S., Connell, C.M., Roberts, E.W., Zhao, Q., Caballero, O.L., et al. (2013). Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. 110, 20212–20217.

29. Vianello, F., Papeta, N., Chen, T., Kraft, P., White, N., Hart, W.K., Kircher, M.F., Swart, E., Rhee, S., Palu, G., et al. (2006). Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/ CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control. J. Immunol. 176, 2902–2914.

30. Seo, Y.D., Jiang, X., Sullivan, K.M., Jalilis, F.G., Smythe, K.S., Abbasi, A., Vignali, M., Park, J.O., Daniel, S.K., Pollack, S.M., et al. (2019). Mobiliza- tion of CD8 T cells via CXCR4 blockade facilitates PD-1 checkpoint ther- apy in human pancreatic cancer. Cell. Cancer Res. 25, 3934–3945.

31. Mullins, I.M., Stingluff, C.L., Lee, J.K., Barbee, C.F., Shu, J., Anderson, S.G., Mayer, M.E., Knaus, W.A., and Mullins, D.W. (2004). CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. 64, 7697–7701.

32. Li, K., Zhu, Z., Luo, J., Fang, J., Zhou, H., Hu, M., Maskey, N., and Yang, G. (2015). Impact of chemokine receptor CXCR3 on tumor-infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer. Int. J. Clin. Exp. Pathol. 8, 14725–14732.

33. Stoli, G., Pol, J., Soumelis, V., Zitvogel, L., and Kroemer, G. (2018). Impact of chemotactic factors and receptors on the cancer immune infil- trate: a bioinformatics study revealing homoegenity and heterogeneity among patient cohorts. Oncoimmunology 7, e1484980.

34. Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M.D., Soni, S., McSkane, M., Baba, H., and Lenz, H.-J. (2018). CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy. Cancer Treat. Rev. 63, 40–47.

35. Bergamaschi, C., Pandit, H., Nagy, B.A., Stellas, D., Jensen, S.M., Bear, J., Cam, M., Valentin, A., Fox, B.A., Felber, B.K., et al. (2020). Hetero- dimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN- γ, CXCL9 and CXCL10. J. Immunther. Cancer 8, e00559.

36. Spranger, S., Dai, D., Horton, B., and Gajewski, T.F. (2017). Tumor- residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 37, 711–723.

37. Spranger, S., Bao, R., and Gajewski, T.F. (2015). Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235.

38. Arenberg, D.A., White, E.S., Burdick, M.D., Strom, S.R., and Strieter, R.M. (2001). Improved survival in tumor-bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10). Cancer Imm- unol. Immunother. 50, 533–538.

39. Moon, E.K., Wang, L.C.S., Bekdache, K., Lynn, R.C., Lo, A., Thorne, S.H., and Albelda, S.M. (2018). Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology 7, e1395997.

40. Moesta, A.K., Cooke, K., Piassecki, J., Mitchell, P., Rottman, J.B., Fitzger- ald, K., Zhan, J., Yang, B., Le, T., Belmontes, B., et al. (2017). Local delivery of OncovEXxGM-CSF generates systemic antitumor immune responses enhanced by cytotoxic T-lymphocyte-associated protein blockade. Clin. Cancer Res. 23, 6190–6202.

41. Yoshimura, T. (2018). The chemokine MCP-1 (CCL2) in the host interac- tion with cancer: a foe or ally? Cell. Mol. Immunol. 15, 335–345.

42. Gschwandtner, M., Derler, R., and Midwood, K.S. (2019). More than just attractive: how CCL2 influences myeloid cell behavior beyond chemo- taxis. Front. Immunol. 10, 2759.

43. Soria, G., and Ben-Baruch, A. (2008). The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 267, 271–285.

44. Argyle, D., and Kitamura, T. (2018). Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors. Front. Immunol. 9, 2629.

45. Loyher, P., Rochefort, J., Chanville, C.B., Hamon, P., Lescaille, G., Ber- tolus, C., Guillot-Desol, M., Krummel, M.F., Lemoine, F.M., Combadière, C., et al. (2016). CCR2 influences T regulatory cell migration to tumors and serves as a biomarker of cyclophosphamide sensitivity. Cancer Res. 76, 6483–6494.

46. Aldinucci, D., and Colombatti, A. (2014). The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm. 2014, 292376.

47. Roberts, E.W., Broz, M.L., Binnewies, M., Headley, M.B., Nelson, A.E., Wolf, D.M., Kaisho, T., Bogunovic, D., Bhardwaj, N., and Krummel, M.F. (2016). Critical role for CD103+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melano- noma. Cancer Cell 30, 324–336.

48. Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoyazarova, M., Agudo, J., Tung, N., et al. (2016). Expansion and activation of CD103+ dendritic cell
progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924–938.

50. Ruffel, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C.M.T., Pryer, N., Daniel, D., Hwang, E.S., Rugo, H.S., and Coussens, L.M. (2014). Macrophage IL-10 blocks CDB+ T cell-dependent responses to chemotherapy by suppressor IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623–637.

51. Böttcher, J.P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrero, M., Sammicheli, S., Rogers, N.C., Sahai, E., Zeilny, S., and Reis e Sousa, C. (2018). NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022–1037.

52. Kumar, V., Patel, S., Tcyganov, E., and Gabrilovich, D.I. (2016). The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208–220.

53. Alfaro, C., Teijeira, A., Onató, C., Pérez, G., Sanmamed, M.F., Andueza, Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C.M.T., Böttcher, J.P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrero, M., Sammicheli, S., Rogers, N.C., Sahai, E., Zeilny, S., and Reis e Sousa, C. (2018). NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022–1037.

54. Mukaida, N., Okamoto, S., Ishikawa, Y., and Matsushima, K. (1994). Molecular mechanism of interleukin-8 gene expression. J. Leukoc. Biol. 56, 554–558.

55. Liu, Q., Li, A., Tian, Y., Wu, J.D., Liu, Y., Li, T., Chen, Y., Han, X., and Wu, A. (2012). Transiently entrapped circulating tumor cells interact with neutrophils by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages. Cell Cycle 11, 2928–2938.

56. Spicer, J.D., McDonald, B., Cools-Lartigue, J.J., Chow, S.C., Giannias, B., Kubes, P., and Ferri, L.E. (2012). Neutrophils promote liver metastasis by IL-8 aggravating atherosclerosis via activation NF-κB signaling in macrophages. Cell Cycle 11, 2928–2938.

57. Jo, L., Liu, Y., Wu, J.D., Liu, Y., Li, T., Chen, Y., Han, X., and Wu, A. (2016). The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev. 37, 61–71.

58. Huh, S.J., Liang, S., Sharma, A., Dong, C., and Robertson, G.P. (2010). Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 70, 6071–6083.

59. Alfaro, C., Suárez, N., Martínez-Forero, I., Palazón, A., Rouzaut, A., Solano, S., Feijoó, E., Gúrpede, A., Bolaños, E., Erro, L., et al. (2011). Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation. PLoS One 6, e17922.

60. Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P.G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V.E., et al. (2012). A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165–178.

61. Crowe, L.A.N., McLean, M., Kitsen, S.M., Melchor, E.G., Patommel, K., Cao, H.M., Reilly, J.H., Leach, W.J., Rooney, B.P., Spencer, S.J., et al. (2019). S100A8 & S100A9: alarmin mediated inflammation in tendinopathy. Sci. Rep. 9, 1463.

62. An, Z., Li, J., Yu, J., Wang, X., Gao, H., Zhang, W., Wei, Z., Zhang, J., Zhang, Y., Zhao, J., et al. (2019). Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages. Cell Cycle 18, 2928–2938.

63. Galon, J., Bruni, D. (2020). Tumor immunology and tumor evolution: interwoven histories. Immunity 52, 55–81.

64. Robert, C. (2020). A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun. 11, 3801.

65. Martens, A., Wistuba-Hamprecht, K., Foppens, M.G., Yuan, J., Postow, M.A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016). Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin. Cancer Res. 22, 2908–2918.

66. Huang, H., Wang, G., Westwood, J.A., Pachynski, R.K., Tiffany, H.L., Marincola, F.M., Wang, E., Young, H.A., Murphy, P.M., and Hwu, P. (2002). Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 13, 1971–1980.

67. Liu, G., Rui, W., Zheng, H., Huang, D., Yu, F., Zhang, Y., Dong, J., Zhao, X., and Lin, X. (2020). CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur. J. Immunol. 50, 712–724.

68. Peng, W., Ye, Y., Rabinovich, B.A., Liu, C., Lou, Y., Zhang, M., Whittington, M., Yang, Y., Overwijk, W.W., Lizée, G., et al. (2010). Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res. 16, 5458–5468.

69. Whilding, L.M., Halim, L., Draper, B., Parente-Pereira, A.C., Zabinski, T., Davies, D.M., and Maher, J. (2019). CAR T-cells targeting the integrin αvβ6 and Co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancer 71, 674.

70. Luker, K.E., Lewin, S.A., Mihalko, L.A., Schmidt, B.T., Winkler, J.S., Coggin, N.L., Thomas, D.G., and Luker, G.D. (2012). Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 31, 4750–4758.

71. Langenes, V., Svensson, H., Börjesson, L., Gustavsson, B., Bemark, M., Sjöling, Å., and Quiding-Järbrink, M. (2013). Expression of the chemokine decoy receptor D6 is decreased in colon adenocarcinomas. Cancer Immunol. Immunother. 62, 1687–1695.

72. Subrahmanyan, P.B., Dong, Z., Gusenleitner, D., Giobbie-Hurder, A., Severgnini, M., Zhou, J., Manos, M., Eastman, L.M., Maecker, H.T., and Hodi, F.S. (2018). Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. Clin. Cancer Res. 24, 563–567.

73. Herbst, R.S., Soria, J.-C., Kowanetz, M., Fine, G.D., Hammond, A., Gordon, M.S., Solsona, J.A., McDermott, D.F., Powel, D.R., Setoh, P.S., et al. (2014). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567.

74. Chow, M.T., Ozga, A.J., Servis, R.L., Frederick, D.T., Lo, J.A., Fisher, D.E., Freeman, G.J., Boland, G.M., and Luster, A.D. (2019). Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity 50, 1498–1512.

75. Sade-Feldman, M., Yizhak, K., Bjorgaard, S.L., Ray, J.P., de Boer, C.G., Jenkins, R.W., Lieb, D.J., Chen, J.H., Frederick, D.T., Bazily-Rokni, M., et al. (2018). Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.

76. Rosenberg, S.A., Spiess, P., and Lafreniere, R. (1986). A new approach to point immunotherapy in melanoma. Cell 44, 998–1013.
Review

97. Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., and Wu, K. (2017). Chimeric
81. Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Solomon, D., Topalian,
98. Morgan, R.A., Johnson, L.A., Davis, J.L., Zheng, Z., Woolard, K.D., Reap,
84. Turtle, C.J., Hanafi, L.-A., Berger, C., Gooley, T.A., Cherian, S., Hudecek,
91. Straathof, K., Flutter, B., Wallace, R., Jain, N., Loka, T., Depani, S.,
95. Heczey, A., Louis, C.U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B.,
82. Del Nagro, C.J., Otero, D.C., Anzelon, A.N., Omori, S.A., Kolla, R.V., and
88. Jo, Y., Ali, L.A., Shim, J.A., Lee, B.H., and Hong, C. (2020). Innovative
89. Mullard, A. (2021). FDA approves fourth CAR-T cell therapy. Nat. Rev.
93. Majzner, R.G., Weber, E.W., Lynn, R.C., Xu, P., and Mackall, C.L. (2018).
86. Prasad, V. (2018). Innovative CAR-T cell therapy: implications for payer and policy makers. Nat. Rev. Clin. Oncol. 15, 11–12.
87. Straathof, K., Futter, B., Wallace, R., Jain, N., Loka, T., Depani, S., Wright, G., Thomas, S., Cheung, G.W.-K., Gileadi, T., et al. (2020). Neurotoxicity associated with a high-affinity GD2 CAR—letter. Cancer Immunol. Res. 8, 494–495.
88. Louis, C.U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G.D., Rosig, C., Russell, H.V., Dilou, O., Liu, E., et al. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050–6056.
89. Johnson, L.A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P.R., McGettigan,
113. Itoh-Nakadai, A., Saito, Y., Murasawa-Tomizawa, M., Kajita, H., Matsushita, S.E., Nace, A.K., Dentchev, T., Thekkat, P., Loew, A., et al. (2015). Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7, 275ra22.
100. Guo, Y., Feng, K., Liu, Y., Wu, Z., Dai, H., Yang, Q., Wang, Y., Jia, H., and Han, W. (2018). Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin. Cancer Res. 24, 1277–1286.
101. Goff, S.L., Morgan, R.A., Yang, J.C., Sherry, R.M., Robbins, P.F., Restifo, N.P., Feldman, S.A., Lu, Y.-C., Lu, L., Zheng, Z., et al. (2019). Pilot trial of adoptive transfer of chimeric antigen receptor transduced T cells targeting EGFRvIII in patients with glioblastoma. J. Immunother. 42, 126–135.
102. Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P.L., Sommerrymeyer, D., Jensen, M.C., Rader, C., and Riddell, S.R. (2013). Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19, 3153–3164.
103. Wallstabe, L., Göttlich, C., Nelke, L.C., Kühnemundt, J., Schwarz, T., Nerrer, T., Einsele, H., Walles, H., Danekar, G., Nizter, S.L., et al. (2019). ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight 4, 126345.
104. Chang, S.S. (2004). Overview of prostate-specific membrane antigen. Rev. Urol. 6, S13–S18.
105. Junghans, R.P., Ma, Q., Rathore, R., Gomes, E.M., Bais, A.J., Lo, A.S.Y., Abedi, M., Davies, R.A., Cabral, H.J., Al-Hornsi, A.S., et al. (2016). Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin-2 T-cell pharmacodynamics as a determinant of clinical response. Prostate 76, 1257–1270.
106. Urbanska, K., Lanitis, E., Poussin, M., Lynn, R.C., Gavin, B.P., Kelderman, S., Yu, J., Scholler, N., and Powell, D.J. (2012). A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72, 1844–1852.
107. Cho, J.H., Collins, J.J., and Wong, W.W. (2018). Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426–1438.
108. Shah, N.N., Johnson, B.D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C.A., Krueger, W., Worden, A.A., Kadan, M.J., Yim, S., et al. (2020). Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med. 26, 1585–1586.
109. Schneider, D., Xiong, Y., Yu, D., Hu, P., Alabanza, L., Steimle, B., Mahmoud, H., Anthony-Gonda, K., Krueger, W., Zhu, Z., et al. (2021). Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci. Transl. Med. 13, eabc8401.
110. Moon, E.K., Wang, L.-C., Dolf, D.V., Wilson, C.B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Puré, E., Milone, M.C., et al. (2014). Multifactorial T-cell phenotype which is reversible can limit the efficacy of chimeric antigen receptor–transduced HSCs in solid tumors. Cell. Clin. Cancer Res. 20, 4262–4273.
111. Emami-Shahri, N., Foster, J., Kashani, R., Gazinskia, P., Cook, C., Sosabowski, J., Maher, J., and Papa, S. (2018). Clinically compliant spatial and temporal imaging of chimeric antigen receptor T cells. Nat. Commun. 9, 1081.
112. Ishii, A., Ito, A., Kono, F., Ohmori, T., Kojima, K., Iwata, Y., Suda, T., and Hori, T. (2017). Chimeric antigen receptor T cells: a novel therapy for solid tumors. J. Hematol. Oncol. 10, 78.
114. Morgan, R.A., Johnson, L.A., Davis, J.L., Zheng, Z., Woolard, K.D., Reap,
22. Elgavish, A., Shen, J.-M., Guo, Y., Feng, K., Liu, Y., Wu, Z., Dai, H., Yang, Q., Wang, Y., Jia, H., and Han, W. (2018). Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin. Cancer Res. 24, 1277–1286.
23. Goff, S.L., Morgan, R.A., Yang, J.C., Sherry, R.M., Robbins, P.F., Restifo, N.P., Feldman, S.A., Lu, Y.-C., Lu, L., Zheng, Z., et al. (2019). Pilot trial of adoptive transfer of chimeric antigen receptor transduced T cells targeting EGFRvIII in patients with glioblastoma. J. Immunother. 42, 126–135.
24. Hudecek, M., Lupo-Stanghellini, M.-T., Kosasih, P.L., Sommerrymeyer, D., Jensen, M.C., Rader, C., and Riddell, S.R. (2013). Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19, 3153–3164.
25. Wallstabe, L., Göttlich, C., Nelke, L.C., Kühnemundt, J., Schwarz, T., Nerrer, T., Einsele, H., Walles, H., Danekar, G., Nizter, S.L., et al. (2019). ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight 4, 126345.
26. Chang, S.S. (2004). Overview of prostate-specific membrane antigen. Rev. Urol. 6, S13–S18.
27. Junghans, R.P., Ma, Q., Rathore, R., Gomes, E.M., Bais, A.J., Lo, A.S.Y., Abedi, M., Davies, R.A., Cabral, H.J., Al-Hornsi, A.S., et al. (2016). Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin-2 T-cell pharmacodynamics as a determinant of clinical response. Prostate 76, 1257–1270.
28. Urbanska, K., Lanitis, E., Poussin, M., Lynn, R.C., Gavin, B.P., Kelderman, S., Yu, J., Scholler, N., and Powell, D.J. (2012). A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72, 1844–1852.
29. Cho, J.H., Collins, J.J., and Wong, W.W. (2018). Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426–1438.
30. Shah, N.N., Johnson, B.D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C.A., Krueger, W., Worden, A.A., Kadan, M.J., Yim, S., et al. (2020). Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med. 26, 1585–1586.
113. Lesch, S., Blumenberg, V., Stoiber, S., Gottschlich, A., Ogonek, J., Cadilha, B.L., Dantes, Z., Rataj, F., Dorman, K., Lutz, J., et al. (2021). T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat. Biomed. Eng. 5, 1–15.

114. Craddock, J.A., Lu, A., Bear, A., Pule, M., Brenner, M.K., Rooney, C.M., and Foster, A.E. (2010). Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33, 780–788.

115. Moon, E.K., Carpenito, C., Sun, J., Wang, L.-C.S., Kapoor, V., Predina, J., Powell, D.J., Riley, J.L., June, C.H., and Albeda, S.M. (2011). Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17, 4719–4730.

116. Brown, C.E., Vishwanath, R.P., Aguilar, B., Starr, R., Najbauer, J., Aboody, K.S., and Jensen, M.C. (2007). Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J. Immunol. 178, 3332–3341.

117. Di Stasi, A., De Angelis, B., Rooney, C.M., Zhang, L., Mahendravada, A., Foo, I., He, H., Brenner, M.K., Dotti, G., and Savoldo, B. (2009). T lymphocytes expressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113, 6392–6402.

118. Rapp, M., Grassmann, S., Chaloupa, M., Layritz, P., Kruger, S., Ormanns, S., Rataj, F., Jansen, K.-P., Endres, S., Anz, D., et al. (2016). C-C chemokine receptor type 4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. Oncoimmunology 5, e1105428.

119. Cadiha, B.L., Benmabarek, M.-R., Dorman, K., Oner, A., Lorenzini, T., Obeck, H., Vantinien, M., Pilato, M.D., Pruessmann, J.N., Stoiber, S., et al. (2021). Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci. Adv. 7, eabi5781.

120. Siddiqui, I., Erre, M., Brekel, M., Debets, R., and Allavena, P. (2016). Enhanced recruitment of genetically modified CXCGR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J. Immunother. Cancer 4, 21.

121. Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., and Tamada, K. (2018). IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat. Biotechnol. 36, 346–351.

122. Luo, H., Su, J., Sun, R., Sun, Y., Wang, Y., Dong, Y., Shi, B., Jiang, H., and Li, Z. (2017). Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion. Clin. Cancer Res. 26, 5494–5505.

123. Sandnam, M.F., Carranza-Rua, O., Alfaro, C., Oñate, C., Martín-Algarra, S., Perez, G., Landazuri, S.F., Gonzalez, A., Gross, S., Rodriguez, I., et al. (2014). Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin. Cancer Res. 20, 5697–5707.

124. Kuwada, Y., Sasaki, T., Morinaka, K., Kitadai, Y., Mukaida, N., and Chayama, K. (2003). Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int. J. Oncol. 22, 765–771.

125. Yang, J., and Richmond, A. (2001). Constitutive IgB kinase activity correlates with nuclear factor-κB activation in human melanoma cells. Cancer Res. 61, 4901–4909.

126. Duckworth, C., Zhang, L., Carroll, S.L., Ethier, S.P., and Cheung, H.W. (2016). Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression. Oncogene 35, 4036–4047.

127. Le Rolle, A.-F., Chiu, T.K., Fara, M., Shia, J., Zeng, Z., Weiser, M.R., Paty, P.B., and Chiu, V.K. (2015). The prognostic significance of CXCL1 hypersecretion by human colorectal cancer epithelia and myofibroblasts. J. Transl. Med. 13, 199.
145. Shields, J.D., Kourtis, I.C., Tomei, A.A., Roberts, J.M., and Swartz, M.A. (2010). Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328, 749–752.

146. Heissmeyer, V., Macián, F., Im, S.-H., Varma, R., Feske, S., Venuprasad, K., Gu, H., Liu, Y.-C., Dustin, M.L., and Rao, A. (2004). Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat. Immunol. 5, 255–265.

147. Legler, D.F., Johnson-Léger, C., Wiedle, G., Bron, C., and Imhof, B.A. (2004). The αvβ3 integrin as a tumor homing ligand for lymphocytes. Eur. J. Immunol. 34, 1608–1616.

148. Tran, E., Chinnasamy, D., Yu, Z., Morgan, R.A., Lee, C.-C.R., Restifo, N.P., and Rosenberg, S.A. (2013). Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 210, 1125–1135.

149. Caruana, L., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E.S., Ittmann, M.M., Marchetti, D., and Dotti, G. (2015). Heparanase promotes tumor infiltration and antitumor activity of CAR-redirectioned T lymphocytes. Nat. Med. 21, 524–529.

150. Zhao, R., Cui, Y., Zheng, Y., Li, S., Lv, J., Wu, Q., Long, Y., Wang, S., Yao, Y., Wei, W., et al. (2021). Human hyaluronidase PH20 potentiates the antitumor activities of mesothelin-specific CAR-T cells against gastric cancer. Front. Immunol. 12, 2785.